vs
Side-by-side financial comparison of Primoris Services Corp (PRIM) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.9B, roughly 1.3× Primoris Services Corp). Zoetis runs the higher net margin — 25.3% vs 2.8%, a 22.5% gap on every dollar of revenue. On growth, Primoris Services Corp posted the faster year-over-year revenue change (6.7% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $121.1M). Over the past eight quarters, Primoris Services Corp's revenue compounded faster (14.7% CAGR vs 4.4%).
Primoris Services Corporation is a publicly traded specialty construction and infrastructure company based in the United States, with a particular focus on pipelines for natural gas, wastewater and water. As of 2014 it was a Fortune 1000 company.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
PRIM vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $2.4B |
| Net Profit | $51.7M | $603.0M |
| Gross Margin | 9.4% | 70.2% |
| Operating Margin | 4.2% | 31.9% |
| Net Margin | 2.8% | 25.3% |
| Revenue YoY | 6.7% | 3.0% |
| Net Profit YoY | -4.2% | 3.8% |
| EPS (diluted) | $0.94 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9B | $2.4B | ||
| Q3 25 | $2.2B | $2.4B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $1.6B | $2.2B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.6B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $51.7M | $603.0M | ||
| Q3 25 | $94.6M | $721.0M | ||
| Q2 25 | $84.3M | $718.0M | ||
| Q1 25 | $44.2M | $631.0M | ||
| Q4 24 | $54.0M | $581.0M | ||
| Q3 24 | $58.4M | $682.0M | ||
| Q2 24 | $49.5M | $624.0M | ||
| Q1 24 | $18.9M | $599.0M |
| Q4 25 | 9.4% | 70.2% | ||
| Q3 25 | 10.8% | 71.5% | ||
| Q2 25 | 12.3% | 73.6% | ||
| Q1 25 | 10.4% | 72.0% | ||
| Q4 24 | 10.6% | 69.5% | ||
| Q3 24 | 12.0% | 70.6% | ||
| Q2 24 | 11.9% | 71.7% | ||
| Q1 24 | 9.4% | 70.6% |
| Q4 25 | 4.2% | 31.9% | ||
| Q3 25 | 6.3% | 37.0% | ||
| Q2 25 | 6.7% | 36.7% | ||
| Q1 25 | 4.3% | 36.5% | ||
| Q4 24 | 5.0% | 31.6% | ||
| Q3 24 | 6.0% | 36.6% | ||
| Q2 24 | 5.5% | 33.0% | ||
| Q1 24 | 3.1% | 34.1% |
| Q4 25 | 2.8% | 25.3% | ||
| Q3 25 | 4.3% | 30.0% | ||
| Q2 25 | 4.5% | 29.2% | ||
| Q1 25 | 2.7% | 28.4% | ||
| Q4 24 | 3.1% | 25.1% | ||
| Q3 24 | 3.5% | 28.6% | ||
| Q2 24 | 3.2% | 26.4% | ||
| Q1 24 | 1.3% | 27.4% |
| Q4 25 | $0.94 | $1.37 | ||
| Q3 25 | $1.73 | $1.63 | ||
| Q2 25 | $1.54 | $1.61 | ||
| Q1 25 | $0.81 | $1.41 | ||
| Q4 24 | $0.98 | $1.29 | ||
| Q3 24 | $1.07 | $1.50 | ||
| Q2 24 | $0.91 | $1.37 | ||
| Q1 24 | $0.35 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $535.5M | — |
| Total DebtLower is stronger | $469.9M | — |
| Stockholders' EquityBook value | $1.7B | $3.3B |
| Total Assets | $4.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $535.5M | — | ||
| Q3 25 | $431.4M | $2.1B | ||
| Q2 25 | $390.3M | $1.4B | ||
| Q1 25 | $351.6M | $1.7B | ||
| Q4 24 | $455.8M | $2.0B | ||
| Q3 24 | $352.7M | $1.7B | ||
| Q2 24 | $207.4M | $1.6B | ||
| Q1 24 | $177.6M | $2.0B |
| Q4 25 | $469.9M | — | ||
| Q3 25 | $486.0M | — | ||
| Q2 25 | $603.1M | — | ||
| Q1 25 | $612.0M | — | ||
| Q4 24 | $734.8M | — | ||
| Q3 24 | $903.7M | — | ||
| Q2 24 | $933.0M | — | ||
| Q1 24 | $951.7M | — |
| Q4 25 | $1.7B | $3.3B | ||
| Q3 25 | $1.6B | $5.4B | ||
| Q2 25 | $1.5B | $5.0B | ||
| Q1 25 | $1.4B | $4.7B | ||
| Q4 24 | $1.4B | $4.8B | ||
| Q3 24 | $1.4B | $5.2B | ||
| Q2 24 | $1.3B | $5.0B | ||
| Q1 24 | $1.2B | $5.1B |
| Q4 25 | $4.4B | $15.5B | ||
| Q3 25 | $4.6B | $15.2B | ||
| Q2 25 | $4.5B | $14.5B | ||
| Q1 25 | $4.2B | $14.1B | ||
| Q4 24 | $4.2B | $14.2B | ||
| Q3 24 | $4.2B | $14.4B | ||
| Q2 24 | $4.0B | $14.2B | ||
| Q1 24 | $4.0B | $14.3B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.9M | $893.0M |
| Free Cash FlowOCF − Capex | $121.1M | $732.0M |
| FCF MarginFCF / Revenue | 6.5% | 30.7% |
| Capex IntensityCapex / Revenue | 1.2% | 6.7% |
| Cash ConversionOCF / Net Profit | 2.76× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $340.5M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.9M | $893.0M | ||
| Q3 25 | $182.9M | $938.0M | ||
| Q2 25 | $78.5M | $486.0M | ||
| Q1 25 | $66.2M | $587.0M | ||
| Q4 24 | $298.3M | $905.0M | ||
| Q3 24 | $222.5M | $951.0M | ||
| Q2 24 | $16.1M | $502.0M | ||
| Q1 24 | $-28.5M | $595.0M |
| Q4 25 | $121.1M | $732.0M | ||
| Q3 25 | $148.4M | $805.0M | ||
| Q2 25 | $45.3M | $308.0M | ||
| Q1 25 | $25.6M | $438.0M | ||
| Q4 24 | $270.0M | $689.0M | ||
| Q3 24 | $158.8M | $784.0M | ||
| Q2 24 | $-8.1M | $370.0M | ||
| Q1 24 | $-38.9M | $455.0M |
| Q4 25 | 6.5% | 30.7% | ||
| Q3 25 | 6.8% | 33.5% | ||
| Q2 25 | 2.4% | 12.5% | ||
| Q1 25 | 1.6% | 19.7% | ||
| Q4 24 | 15.5% | 29.7% | ||
| Q3 24 | 9.6% | 32.8% | ||
| Q2 24 | -0.5% | 15.7% | ||
| Q1 24 | -2.8% | 20.8% |
| Q4 25 | 1.2% | 6.7% | ||
| Q3 25 | 1.6% | 5.5% | ||
| Q2 25 | 1.8% | 7.2% | ||
| Q1 25 | 2.5% | 6.7% | ||
| Q4 24 | 1.6% | 9.3% | ||
| Q3 24 | 3.9% | 7.0% | ||
| Q2 24 | 1.5% | 5.6% | ||
| Q1 24 | 0.7% | 6.4% |
| Q4 25 | 2.76× | 1.48× | ||
| Q3 25 | 1.93× | 1.30× | ||
| Q2 25 | 0.93× | 0.68× | ||
| Q1 25 | 1.50× | 0.93× | ||
| Q4 24 | 5.53× | 1.56× | ||
| Q3 24 | 3.81× | 1.39× | ||
| Q2 24 | 0.32× | 0.80× | ||
| Q1 24 | -1.50× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
